breast cancer

Fleur Mauritz MD discusses the 10-year follow-up findings from the RAPCHEM study, presented at the EBCC 2026. The research indicates that risk-based radiotherapy de-escalation is safe and effective following primary systemic therapy for early breast cancer patients. This approach allows for tailored treatment, potentially reducing side effects without compromising low recurrence rates. The study provides crucial long-term evidence supporting individualized radiotherapy strategies.

At the 2026 EBCC, Jelle Wesseling MD PhD discusses the LORD-trial, which found active surveillance for low-risk, estrogen-receptor-positive, HER2-negative, grade 1–2 DCIS is as effective as standard therapy. The trial's reassuring findings led to early cessation of randomization, supporting de-escal

Elisa Agostinetto MD presented at EBCC 2026, highlighting circulating tumor DNA (ctDNA) as a superior prognostic marker over clinical indicators for predicting relapse and progression in early breast cancer patients after neoadjuvant therapy. This research supports ctDNA for post-neoadjuvant risk st

Kerstin Wimmer MD, at the 2026 EBCC, discussed the OPBC-09 PRExRT study findings, revealing that polyurethane-coated breast implants significantly reduce capsular contracture risk for breast cancer patients receiving mastectomy with immediate pre-pectoral reconstruction followed by radiotherapy. Thi

At EBCC 2026, Fatima Cardoso MD discussed the OASIS-4 trial, revealing elinzanetant greatly reduced vasomotor symptoms ("hot flashes") in breast cancer patients receiving endocrine therapy. This dual neurokinin receptor antagonist demonstrated rapid and sustained efficacy across various ET types, of

Elisabetta Bonzano MD PhD discusses the BRAVE-HEART study at the 2025 EBCC, revealing how the Active Breathing Co-ordination (ABC) system significantly halves the coronary radiation dose during left breast irradiation. This crucial finding confirms ABC's high feasibility and clinical impact in reduc

This episode features Philip Poortmans MD PhD, University of Antwerp & Iridium Netwerk, discussing key themes from the 2026 European Breast Cancer Conference. He focuses on individualizing breast cancer therapy through de-escalation, covering the EUROPA trial, radiation boost data, axillary radiothe

Tess Snellen MD, from the Netherlands Cancer Institute, presents key findings at the EBCC 2026 regarding a molecular test. This innovative test utilizes next-generation sequencing to precisely differentiate between a recurrent ipsilateral breast cancer and a new primary tumor, significantly aiding i

Hope S. Rugo, MD, discusses the Phase III evERA Breast Cancer trial at SABCS 2025, revealing clinically meaningful improvements with giredestrant plus everolimus for ER-positive, HER2-negative metastatic breast cancer previously treated with a CDK4/6 inhibitor. Subgroup analyses show benefits regard